{"id":"octreotide","rwe":[{"pmid":"41905700","year":"2026","title":"Effect of octreotide-deoxycholate hydrophobic ion pairing solid dispersions on intestinal permeability to enhance octreotide absorption via increased lipophilicity and ASBT-mediated transport.","finding":"","journal":"International journal of pharmaceutics","studyType":"Clinical Study"},{"pmid":"41894844","year":"2026","title":"Pulmonary neuroendocrine tumour-associated ectopic Cushing's syndrome: diagnostic challenges and multidisciplinary management.","finding":"","journal":"Endocrinology, diabetes & metabolism case reports","studyType":"Clinical Study"},{"pmid":"41878918","year":"2026","title":"[Optimal timing for octreotide administration in adult patients with chylothorax: A scoping review].","finding":"","journal":"Nutricion hospitalaria","studyType":"Clinical Study"},{"pmid":"41877371","year":"2026","title":"Adult-Onset Nesidioblastosis: A Challenging Diagnosis Revealed by Endoscopic Ultrasonography.","finding":"","journal":"The American journal of case reports","studyType":"Clinical Study"},{"pmid":"41874019","year":"2026","title":"Isolated Blunt Pancreatic Head Injury with Evolving Acute Peripancreatic Fluid Collection in a Child Successfully Managed Conservatively.","finding":"","journal":"Pediatric reports","studyType":"Clinical Study"}],"_fda":{"id":"a12a7206-6077-4b61-a038-4aae1170b387","set_id":"01962c67-e551-47b6-a276-e1ae1860d2a4","openfda":{"unii":["75R0U2568I"],"route":["INTRAVENOUS","SUBCUTANEOUS"],"rxcui":["312068","312069","312070"],"spl_id":["a12a7206-6077-4b61-a038-4aae1170b387"],"brand_name":["Octreotide Acetate"],"spl_set_id":["01962c67-e551-47b6-a276-e1ae1860d2a4"],"package_ndc":["71288-566-01","71288-566-02","71288-567-01","71288-567-02","71288-568-01","71288-568-02"],"product_ndc":["71288-566","71288-567","71288-568"],"generic_name":["OCTREOTIDE ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["OCTREOTIDE ACETATE"],"manufacturer_name":["Meitheal Pharmaceuticals, Inc."],"application_number":["ANDA075957"],"is_original_packager":[true]},"version":"1","pregnancy":["8.1 Pregnancy Risk Summary The limited data with octreotide acetate injection in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, no adverse developmental-effects were observed with IV administration of octreotide to pregnant rats and rabbits during organogenesis at doses 7- and 13-times, respectively the maximum recommended human dose (MRHD) of 1.5 mg/day based on body surface area (BSA). Transient growth retardation, with no impact on postnatal development, was observed in rat offspring from a pre- and post-natal study of octreotide at IV doses below the MRHD based on BSA ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data In postmarketing data, a limited number of exposed pregnancies have been reported in patients with acromegaly. Most women were exposed to octreotide during the first trimester of pregnancy at doses ranging from 100 to 300 mcg/day of octreotide acetate injection or 20 mg to 30 mg once a month of octreotide acetate for injectable suspension, however some women elected to continue octreotide therapy throughout pregnancy. In cases with a known outcome, no congenital malformations were reported. Animal Data In embryo-fetal development studies in rats and rabbits, pregnant animals received IV doses of octreotide up to 1 mg/kg/day during the period of organogenesis. A slight reduction in body weight gain was noted in pregnant rats at 0.1 and 1 mg/kg/day. There were no maternal effects in rabbits or embryo-fetal effects in either species up to the maximum dose tested. At 1 mg/kg/day in rats and rabbits, the dose multiple was approximately 7- and 13-times, respectively, at the highest recommended human dose of 1.5 mg/day based on BSA. In a pre- and post-natal development rat study at IV doses of 0.02-1 mg/kg/day, a transient growth retardation of the offspring was observed at all doses which was possibly a consequence of GH inhibition by octreotide. The doses attributed to the delayed growth are below the human dose of 1.5 mg/day, based on BSA."],"overdosage":["10 OVERDOSAGE A limited number of accidental overdoses of octreotide acetate injection in adults have been reported. In adults, the doses ranged from 2,400 to 6,000 mcg/day administered by continuous infusion (100 to 250 mcg/hour) or subcutaneously (1,500 mcg 3 times a day). Adverse events in some patients included arrhythmia, complete atrioventricular block, hypotension, cardiac arrest, brain hypoxia, pancreatitis, hepatitis steatosis, hepatomegaly, lactic acidosis, flushing, diarrhea, lethargy, weakness, and weight loss. If overdose occurs, symptomatic management is indicated. Up-to-date information about the treatment of overdose can often be obtained from the National Poison Control Center at 1-800-222-1222."],"description":["11 DESCRIPTION Octreotide Acetate Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous or intravenous injection. Octreotide acetate, known chemically as L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-,cyclic (2 → 7)-disulfide; [R-(R*, R*)] acetate salt, is a long-acting octapeptide with pharmacologic actions mimicking those of the natural hormone somatostatin. Octreotide Acetate Injection is available as sterile 1-mL vials in 3 strengths, containing 50 mcg, 100 mcg, or 500 mcg octreotide (as acetate). Each vial also contains glacial acetic acid, USP (2 mg), mannitol, USP (45 mg), sodium acetate trihydrate, USP (2 mg), water for injection, USP (quantity sufficient to 1 mL). Glacial acetic acid, USP and sodium acetate trihydrate, USP are added to provide a buffered solution, pH to 4.2 ± 0.5. The molecular weight of octreotide acetate is 1019.3 g/mol (free peptide, C 49 H 66 N 10 O 10 S 2 ) and its amino acid sequence is: Structural image"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Octreotide Acetate Injection is available in 1 mL single-dose vials as follows: NDC Octreotide Acetate Injection Package Factor 71288- 566 -02 50 mcg per mL Single-Dose Vial 10 vials per carton 71288- 567 -02 100 mcg per mL Single-Dose Vial 10 vials per carton 71288- 568 -02 500 mcg per mL Single-Dose Vial 10 vials per carton Storage and Handling For prolonged storage, Octreotide Acetate Injection single-dose vials should be stored at refrigerated temperatures 2°C to 8°C (36°F to 46°F) and store in outer carton in order to protect from light. At room temperature (20°C to 30°C or 70°F to 86°F), Octreotide Acetate Injection is stable for 14 days if protected from light. The solution can be allowed to come to room temperature prior to administration. Do not warm artificially. Vials should be opened just prior to administration and the unused portion discarded. Dispose unused product or waste properly. Octreotide Acetate Injection is stable in sterile isotonic saline solutions or sterile solutions of dextrose 5% in water for 24 hours. Sterile, Nonpyrogenic. Preservative-free. The container closure is not made with natural rubber latex."],"geriatric_use":["8.5 Geriatric Use Clinical studies of octreotide acetate injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use Safety and efficacy of octreotide acetate injection in the pediatric population have not been demonstrated. No formal controlled clinical trials have been performed to evaluate the safety and effectiveness of octreotide acetate injection in pediatric patients under age 6 years. In postmarketing reports, serious adverse events, including hypoxia, necrotizing enterocolitis, and death, have been reported with octreotide acetate injection use in children, most notably in children under 2 years of age. The relationship of these events to octreotide has not been established as the majority of these pediatric patients had serious underlying co-morbid conditions. The efficacy and safety of octreotide acetate injection using the octreotide acetate for injectable suspension formulation was examined in a single randomized, double-blind, placebo-controlled, 6 month pharmacokinetics study in 60 pediatric patients age 6 to 17 years with hypothalamic obesity resulting from cranial insult. The mean octreotide concentration after 6 doses of 40 mg octreotide acetate for injectable suspension administered by intramuscular (IM) injection every 4 weeks was approximately 3 ng/mL. Steady-state concentrations was achieved after 3 injections of a 40-mg dose. Mean body mass index (BMI) increased 0.1 kg/m 2 in octreotide acetate for injectable suspension-treated subjects compared to 0.0 kg/m 2 in saline control-treated subjects. Efficacy was not demonstrated. Diarrhea occurred in 11 of 30 (37%) patients treated with octreotide acetate for injectable suspension. No unexpected adverse events were observed. However, with octreotide acetate for injectable suspension at 40 mg once a month, the incidence of new cholelithiasis in this pediatric population (33%) was higher than that seen in other adult indications such as acromegaly (22%) or malignant carcinoid syndrome (24%), where octreotide acetate for injectable suspension was 10 mg to 30 mg once a month."],"effective_time":"20250116","pharmacodynamics":["12.2 Pharmacodynamics Octreotide substantially reduces GH and/or IGF-1 (somatomedin C) levels in patients with acromegaly. Single doses of octreotide have been shown to inhibit gallbladder contractility and to decrease bile secretion in normal volunteers. In controlled clinical trials, the incidence of gallstone or biliary sludge formation was markedly increased [see Warnings and Precautions (5.2)] . Octreotide suppresses secretion of TSH."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption After subcutaneous injection, octreotide is absorbed rapidly and completely from the injection site. Peak concentrations of 5.2 ng/mL (100-mcg dose) were reached 0.4 hours after dosing. Using a specific radioimmunoassay, IV and subcutaneous doses were found to be bioequivalent. Peak concentrations and area under the curve (AUC) values were dose proportional after IV single doses up to 200 mcg and subcutaneous single doses up to 500 mcg and after subcutaneous multiple doses up to 500 mcg 3 times a day (1,500 mcg/day). In patients with acromegaly, a mean peak concentration of 2.8 ng/mL (100-mcg dose) was reached in 0.7 hours after subcutaneous dosing. Distribution In healthy volunteers, the distribution of octreotide from plasma was rapid (tα½ = 0.2 h), the volume of distribution (V dss ) was estimated to be 13.6 L, and the total body clearance ranged from 7 L/hr to 10 L/hr. In blood, the distribution into the erythrocytes was found to be negligible and about 65% was bound in the plasma in a concentration-independent manner. Binding was mainly to lipoprotein and, to a lesser extent, to albumin. In patients with acromegaly, the volume of distribution (V dss ) was estimated to be 21.6 ± 8.5 L, and the total body clearance was increased to 18 L/h. The mean percent of the drug bound was 41.2%. Elimination The elimination of octreotide from plasma had an apparent half-life of 1.7 to 1.9 hours compared with 1 to 3 minutes with the natural hormone. The duration of action of octreotide acetate injection is variable but extends up to 12 hours depending upon the type of tumor. About 32% of the dose is excreted unchanged into the urine. In an elderly population, dose adjustments may be necessary due to a significant increase in the half-life (46%) and a significant decrease in the clearance (26%) of the drug. In patients with acromegaly, the disposition and elimination half-lives were similar to normal subjects. Specific Populations Renal Impairment In patients with mild renal impairment (CL CR 40 to 60 mL/min), octreotide t 1/2 was 2.4 hours and total body clearance was 8.8 L/hr, in moderate impairment (CL CR 10 to 39 mL/min) t 1/2 was 3.0 hours and total body clearance 7.3 L/hr. In patients with severe renal impairment not requiring dialysis (CL CR < 10 mL/min), octreotide t 1/2 was 3.1 hours and total body clearance was 7.6 L/hr. In patients with severe renal failure requiring dialysis, total body clearance was reduced to about half that found in healthy subjects (from approximately 10 L/hr to 4.5 L/hr). Hepatic Impairment Patients with liver cirrhosis showed prolonged elimination of drug, with octreotide t 1/2 increasing to 3.7 hr and total body clearance decreasing to 5.9 L/hr, whereas patients with fatty liver disease showed t 1/2 increased to 3.4 hr and total body clearance of 8.2 L/hr."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Complete Atrioventricular Block [see Warnings and Precautions (5.1)] Cholelithiasis and Complications of Cholelithiasis [see Warnings and Precautions (5.2)] Hyperglycemia and Hypoglycemia [see Warnings and Precautions (5.3)] Thyroid Function Abnormalities [see Warnings and Precautions (5.4)] Steatorrhea and Malabsorption of Dietary Fats [see Warnings and Precautions (5.5)] Changes in Vitamin B12 Levels [see Warnings and Precautions (5.6)] Most common adverse reactions (incidence > 10%) in patients with acromegaly are gallbladder abnormalities, sinus bradycardia, diarrhea, loose stools, nausea, abdominal discomfort, hyperglycemia, and hypothyroidism. In other patients, most common adverse reactions (incidence > 10%) are gallbladder abnormalities. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Gallbladder Abnormalities Gallbladder abnormalities, especially stones and/or biliary sludge, frequently develop in patients on chronic octreotide acetate injection therapy [see Warnings and Precautions (5.1)] . In clinical trials (primarily patients with acromegaly or psoriasis), the incidence of biliary tract abnormalities was 63% (27% gallstones, 24% sludge without stones, 12% biliary duct dilatation). The incidence of stones or sludge in patients who received octreotide acetate injection for 12 months or longer was 52%. Less than 2% of patients treated with octreotide acetate injection for 1 month or less developed gallstones. Cardiac In acromegalics, sinus bradycardia (< 50 bpm) developed in 25%; conduction abnormalities occurred in 10% and arrhythmias developed in 9% of patients during octreotide acetate injection therapy [see Warnings and Precautions (5.1)] . Gastrointestinal Diarrhea, loose stools, nausea, and abdominal discomfort were each seen in 34% to 61% of acromegalic patients in U.S. studies. 2.6% of the patients discontinued therapy due to these symptoms. These symptoms were seen in 5% to 10% of patients with carcinoid tumors and VIPomas. The frequency of these symptoms was not dose related, but diarrhea and abdominal discomfort generally resolved more quickly in patients treated with 300 mcg/day than in those treated with 750 mcg/day. Vomiting, flatulence, abnormal stools, abdominal distention, and constipation were each seen in less than 10% of patients. In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, abdominal tenderness, and guarding. Hypo/Hyperglycemia Hypoglycemia and hyperglycemia occurred in 3% and 16% of acromegalic patients, respectively, but only in about 1.5% of other patients. Symptoms of hypoglycemia were noted in approximately 2% of patients. Hypothyroidism In acromegalics, biochemical hypothyroidism alone occurred in 12% while goiter occurred in 8% and 4% required initiation of thyroid replacement therapy during octreotide acetate injection therapy [see Warnings and Precautions (5.4)] . In patients without acromegaly, hypothyroidism has only been reported in several isolated patients and goiter has not been reported. Other Adverse Events Pain on injection was reported in 7.7%, headache in 6%, and dizziness in 5%. Pancreatitis was also observed [see Warnings and Precautions (5.2)] . Other Adverse Events 1% to 4% Other events, each observed in 1% to 4% of patients, included fatigue, weakness, pruritus, joint pain, backache, urinary tract infection, cold symptoms, flu symptoms, injection site hematoma, bruise, edema, flushing, blurred vision, pollakiuria, fat malabsorption, hair loss, visual disturbance, and depression. Anaphylactoid reactions, including anaphylactic shock, have been reported in several patients receiving octreotide acetate injection. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of octreotide acetate injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hepatobiliary : cholelithiasis, cholecystitis, cholangitis and pancreatitis, which have sometimes required cholecystectomy Gastrointestinal : intestinal obstruction, pancreatic exocrine insufficiency Hematologic : thrombocytopenia"],"contraindications":["4 CONTRAINDICATIONS Sensitivity to this drug or any of its components. Sensitivity to this drug or any of its components. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS The following drugs require monitoring and possible dose adjustment when used with octreotide acetate injection : cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine. ( 7 ) Lutetium Lu 177 Dotatate Injection : Discontinue octreotide acetate injection at least 24 hours prior to each lutetium Lu 177 dotatate dose. ( 7.6 ) 7.1 Cyclosporine Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. Concomitant administration of octreotide acetate injection with cyclosporine may decrease blood levels of cyclosporine and result in transplant rejection. 7.2 Insulin and Oral Hypoglycemic Drugs Octreotide inhibits the secretion of insulin and glucagon. Therefore, blood glucose levels should be monitored when octreotide acetate injection treatment is initiated or when the dose is altered and anti-diabetic treatment should be adjusted accordingly. 7.3 Bromocriptine Concomitant administration of octreotide and bromocriptine increases the availability of bromocriptine. 7.4 Other Concomitant Drug Therapy Concomitant administration of bradycardia-inducing drugs (e.g., beta-blockers) may have an additive effect on the reduction of heart rate associated with octreotide. Dose adjustments of concomitant medication may be necessary. Octreotide has been associated with alterations in nutrient absorption, so it may have an effect on absorption of orally administered drugs. 7.5 Drug Metabolism Interactions Limited published data indicate that somatostatin analogs might decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of GH. Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine) should therefore be used with caution. 7.6 Lutetium Lu 177 Dotatate Injection Octreotide competitively binds to somatostatin receptors and may interfere with the efficacy of lutetium Lu 177 dotatate. Discontinue octreotide acetate injection at least 24 hours prior to each lutetium Lu 177 dotatate dose."],"how_supplied_table":["<table width=\"100%\" styleCode=\"Noautorules\"><caption/><tbody><tr><td><content styleCode=\"bold\">NDC</content></td><td><content styleCode=\"bold\">Octreotide Acetate Injection</content></td><td><content styleCode=\"bold\">Package Factor</content></td></tr><tr><td>71288-<content styleCode=\"bold\">566</content>-02 </td><td>50 mcg per mL Single-Dose Vial </td><td>10 vials per carton </td></tr><tr><td>71288-<content styleCode=\"bold\">567</content>-02 </td><td>100 mcg per mL Single-Dose Vial </td><td>10 vials per carton </td></tr><tr><td>71288-<content styleCode=\"bold\">568</content>-02 </td><td>500 mcg per mL Single-Dose Vial</td><td>10 vials per carton </td></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Octreotide acetate injection exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and VIP secreting adenomas (watery diarrhea)."],"recent_major_changes":["Warnings and Precautions, Steatorrhea and Malabsorption of Dietary Fats ( 5.5 ) 07/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Octreotide acetate injection exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, VIP, secretin, motilin, and pancreatic polypeptide. By virtue of these pharmacological actions, octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and VIP secreting adenomas (watery diarrhea). 12.2 Pharmacodynamics Octreotide substantially reduces GH and/or IGF-1 (somatomedin C) levels in patients with acromegaly. Single doses of octreotide have been shown to inhibit gallbladder contractility and to decrease bile secretion in normal volunteers. In controlled clinical trials, the incidence of gallstone or biliary sludge formation was markedly increased [see Warnings and Precautions (5.2)] . Octreotide suppresses secretion of TSH. 12.3 Pharmacokinetics Absorption After subcutaneous injection, octreotide is absorbed rapidly and completely from the injection site. Peak concentrations of 5.2 ng/mL (100-mcg dose) were reached 0.4 hours after dosing. Using a specific radioimmunoassay, IV and subcutaneous doses were found to be bioequivalent. Peak concentrations and area under the curve (AUC) values were dose proportional after IV single doses up to 200 mcg and subcutaneous single doses up to 500 mcg and after subcutaneous multiple doses up to 500 mcg 3 times a day (1,500 mcg/day). In patients with acromegaly, a mean peak concentration of 2.8 ng/mL (100-mcg dose) was reached in 0.7 hours after subcutaneous dosing. Distribution In healthy volunteers, the distribution of octreotide from plasma was rapid (tα½ = 0.2 h), the volume of distribution (V dss ) was estimated to be 13.6 L, and the total body clearance ranged from 7 L/hr to 10 L/hr. In blood, the distribution into the erythrocytes was found to be negligible and about 65% was bound in the plasma in a concentration-independent manner. Binding was mainly to lipoprotein and, to a lesser extent, to albumin. In patients with acromegaly, the volume of distribution (V dss ) was estimated to be 21.6 ± 8.5 L, and the total body clearance was increased to 18 L/h. The mean percent of the drug bound was 41.2%. Elimination The elimination of octreotide from plasma had an apparent half-life of 1.7 to 1.9 hours compared with 1 to 3 minutes with the natural hormone. The duration of action of octreotide acetate injection is variable but extends up to 12 hours depending upon the type of tumor. About 32% of the dose is excreted unchanged into the urine. In an elderly population, dose adjustments may be necessary due to a significant increase in the half-life (46%) and a significant decrease in the clearance (26%) of the drug. In patients with acromegaly, the disposition and elimination half-lives were similar to normal subjects. Specific Populations Renal Impairment In patients with mild renal impairment (CL CR 40 to 60 mL/min), octreotide t 1/2 was 2.4 hours and total body clearance was 8.8 L/hr, in moderate impairment (CL CR 10 to 39 mL/min) t 1/2 was 3.0 hours and total body clearance 7.3 L/hr. In patients with severe renal impairment not requiring dialysis (CL CR < 10 mL/min), octreotide t 1/2 was 3.1 hours and total body clearance was 7.6 L/hr. In patients with severe renal failure requiring dialysis, total body clearance was reduced to about half that found in healthy subjects (from approximately 10 L/hr to 4.5 L/hr). Hepatic Impairment Patients with liver cirrhosis showed prolonged elimination of drug, with octreotide t 1/2 increasing to 3.7 hr and total body clearance decreasing to 5.9 L/hr, whereas patients with fatty liver disease showed t 1/2 increased to 3.4 hr and total body clearance of 8.2 L/hr. 12.6 Immunogenicity Evaluation of 20 patients treated for at least 6 months has failed to demonstrate titers of antibodies exceeding background levels. However, antibody titers to octreotide acetate injection were subsequently reported in 3 patients and resulted in prolonged duration of drug action in 2 patients."],"indications_and_usage":["1 INDICATIONS AND USAGE Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Octreotide Acetate Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) 1.1 Acromegaly Octreotide Acetate Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. 1.2 Carcinoid Tumors Octreotide Acetate Injection is indicated for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors. 1.3 Vasoactive Intestinal Peptide Tumors Octreotide Acetate Injection is indicated for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas)-secreting tumors. 1.4 Important Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Octreotide Acetate Injection; these trials were not optimally designed to detect such effects."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Cardiac Function Abnormalities : Increased risk for higher degree of atrioventricular blocks. Consider cardiac monitoring in patients receiving octreotide acetate injection intravenously. Bradycardia, arrhythmias, or conduction abnormalities may occur. Use with caution in at-risk patients. Dosage adjustment of cardiac medications may be necessary. ( 5.1 ) Cholelithiasis and Complications of Cholelithiasis : Monitor periodically. Discontinue if complications of cholelithiasis are suspected. ( 5.2 ) Glucose Metabolism : Hypoglycemia or hyperglycemia may occur. Glucose monitoring is recommended and anti-diabetic treatment may need adjustment. ( 5.3 ) Thyroid Function : Hypothyroidism may occur. Monitor thyroid levels periodically. ( 5.4 ) Steatorrhea and Malabsorption of Dietary Fats : New onset steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency. ( 5.5 ) 5.1 Cardiac Function Abnormalities Complete Atrioventricular Block Patients who receive octreotide acetate injection intravenously may be at increased risk for higher degree atrioventricular blocks. In postmarketing reports, complete atrioventricular block was reported in patients receiving IV octreotide acetate injection during surgical procedures. In the majority of patients, octreotide acetate injection was given at higher than recommended doses and/or as a continuous IV infusion. The safety of continuous IV infusion has not been established in patients receiving octreotide acetate injection for the approved indications. Consider cardiac monitoring in patients receiving octreotide acetate injection intravenously. Other Cardiac Conduction Abnormalities Other cardiac conduction abnormalities have occurred during treatment with octreotide acetate injection. In acromegalic patients, bradycardia (< 50 bpm) developed in 25%; conduction abnormalities occurred in 10% and arrhythmias occurred in 9% of patients during octreotide acetate injection therapy [see Adverse Reactions (6)] . Other electrocardiogram (ECG) changes observed included QT prolongation, axis shifts, early repolarization, low voltage, R/S transition, and early R-wave progression. These ECG changes are not uncommon in acromegalic patients. Dose adjustments in drugs such as beta-blockers that have bradycardia effects may be necessary. In one acromegalic patient with severe congestive heart failure (CHF), initiation of octreotide acetate injection therapy resulted in worsening of CHF with improvement when drug was discontinued. Confirmation of a drug effect was obtained with a positive rechallenge. 5.2 Cholelithiasis and Complications of Cholelithiasis Octreotide acetate injection may inhibit gallbladder contractility and decrease bile secretion, which may lead to gallbladder abnormalities or sludge. Acute cholecystitis, ascending cholangitis, biliary obstruction, cholestatic hepatitis, or pancreatitis have been reported with octreotide acetate injection therapy. In clinical trials (primarily patients with acromegaly or psoriasis), the incidence of biliary tract abnormalities was 63% (27% gallstones, 24% sludge without stones, 12% biliary duct dilatation). The incidence of stones or sludge in patients who received octreotide acetate injection for 12 months or longer was 52%. Less than 2% of patients treated with octreotide acetate injection for 1 month or less developed gallstones. One patient developed ascending cholangitis during octreotide acetate injection therapy and died. If complications of cholelithiasis are suspected, discontinue octreotide acetate injection and treat appropriately. 5.3 Hyperglycemia and Hypoglycemia Octreotide acetate injection alters the balance between the counter-regulatory hormones, insulin, glucagon and GH, which may result in hypoglycemia or hyperglycemia. The hypoglycemia or hyperglycemia which occurs during octreotide acetate injection therapy is usually mild but may result in overt diabetes mellitus or necessitate dose changes in insulin or other anti-diabetic agents. Hypoglycemia and hyperglycemia occurred on octreotide acetate injection in 3% and 16% of acromegalic patients, respectively [see Adverse Reactions (6)] . Severe hyperglycemia, subsequent pneumonia, and death following initiation of octreotide acetate injection therapy was reported in one patient with no history of hyperglycemia. Monitor glucose levels during octreotide acetate injection therapy. Adjust dosing of insulin or other anti-diabetic therapy accordingly. 5.4 Thyroid Function Abnormalities Octreotide suppresses secretion of thyroid stimulating hormone (TSH), which may result in hypothyroidism. Baseline and periodic assessment of thyroid function (TSH, total, and/or free T 4 ) is recommended during chronic therapy [see Adverse Reactions (6)] . 5.5 Steatorrhea and Malabsorption of Dietary Fats New onset steatorrhea, stool discoloration and loose stools have been reported in patients receiving somatostatin analogs, including octreotide acetate. Somatostatin analogs reversibly inhibit secretion of pancreatic enzymes and bile acids, which may result in malabsorption of dietary fats and subsequent symptoms of steatorrhea, loose stools, abdominal bloating, and weight loss. If new occurrence or worsening of these symptoms are reported in patients receiving octreotide acetate, evaluate patients for potential pancreatic exocrine insufficiency and manage accordingly. 5.6 Changes in Vitamin B12 Levels Depressed vitamin B 12 levels and abnormal Schilling’s tests have been observed in some patients receiving octreotide acetate injection therapy, and monitoring of vitamin B 12 levels is recommended during octreotide acetate injection therapy."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies in laboratory animals have demonstrated no mutagenic potential of octreotide acetate injection. No carcinogenic potential was demonstrated in mice treated subcutaneously for 85 to 99 weeks at doses up to 2,000 mcg/kg/day (8 x the human exposure based on BSA). In a 116-week subcutaneous study in rats, a 27% and 12% incidence of injection-site sarcomas or squamous cell carcinomas was observed in males and females, respectively, at the highest dose level of 1,250 mcg/kg/day (10 x the human exposure based on BSA) compared to an incidence of 8% to 10% in the vehicle-control groups. The increased incidence of injection-site tumors was most probably caused by irritation and the high sensitivity of the rat to repeated subcutaneous injections at the same site. Rotating injection sites would prevent chronic irritation in humans. There have been no reports of injection-site tumors in patients treated with octreotide acetate for up to 5 years. There was also a 15% incidence of uterine adenocarcinomas in the 1,250 mcg/kg/day females compared to 7% in the saline-control females and 0% in the vehicle-control females. The presence of endometritis coupled with the absence of corpora lutea, the reduction in mammary fibroadenomas, and the presence of uterine dilatation suggest that the uterine tumors were associated with estrogen dominance in the aged female rats which does not occur in humans. Octreotide did not impair fertility in rats at doses up to 1,000 mcg/kg/day, which represents 7-times the human exposure based on BSA."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Sterile Subcutaneous Injection Technique Careful instruction in sterile subcutaneous injection technique should be given to the patients and to other persons who may administer octreotide acetate injection. Cholelithiasis and Complications of Cholelithiasis Advise patients to contact their healthcare provider if they experience signs or symptoms of gallstones (cholelithiasis) or complications of cholelithiasis (e.g., cholecystitis, cholangitis, and pancreatitis) [see Warnings and Precautions (5.2)] . Steatorrhea and Malabsorption of Dietary Fats Advise patients to contact their healthcare provider if they experience new or worsening of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss [see Warnings and Precautions (5.5)] . Pregnancy Inform female patients that treatment with octreotide acetate injection may result in unintended pregnancy [see Use in Specific Populations (8.3)] . meitheal ® Mfd. for Meitheal Pharmaceuticals Chicago, IL 60631 (USA) ©2024 Meitheal Pharmaceuticals Inc. Mfd. by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Nanjing, China 210061 September 2024 8S7AAM9-00"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Octreotide Acetate injection may be administered subcutaneously or intravenously. ( 2.1 ) Acromegaly : Recommended initial Octreotide Acetate injection dosage is 50 mcg three times daily during the initial 2 weeks of therapy. Maintenance dose 100 mcg to 500 mcg three times daily. ( 2.2 ) Carcinoid Tumors : Recommended dosage range of 100 mcg to 600 mcg daily in two to four divided doses during the initial 2 weeks of therapy. ( 2.3 ) VIPomas : Recommended dosage range of 200 mcg to 300 mcg daily in two to four divided doses during the initial 2 weeks of therapy. ( 2.4 ) 2.1 Dosage and Administration Overview Octreotide Acetate injection may be administered subcutaneously or intravenously. Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose. Sites should be rotated in a systematic manner. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if particulates and/or discoloration are observed. Octreotide Acetate injection is not compatible in Total Parenteral Nutrition solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product. Octreotide Acetate injection may be diluted in volumes of 50 mL to 200 mL and infused intravenously over 15 to 30 minutes or administered by intravenous (IV) push over 3 minutes. In emergency situations (e.g., carcinoid crisis), it may be given by rapid bolus. Assess total and/or free T4 levels at baseline and periodically during chronic octreotide acetate therapy. 2.2 Recommended Dosage and Monitoring for Acromegaly The recommended initial dosage of octreotide acetate is 50 mcg three times daily to be administered subcutaneously. Increase octreotide acetate dose based upon GH or IGF-1 levels. The goal is to achieve GH levels less than 5 ng/mL or IGF-1 levels within normal range. Monitor GH or IGF-1 every two weeks after initiating octreotide acetate therapy or with dosage change, and to guide titration. The most common dosage is 100 mcg three times daily, but some patients require up to 500 mcg three times daily for maximum effectiveness. Doses greater than 300 mcg/day seldom result in additional biochemical benefit, and if an increase in dose fails to provide additional benefit, the dose should be reduced. Octreotide Acetate injection should be withdrawn yearly for approximately 4 weeks from patients who have received irradiation to assess disease activity. If GH or IGF-1 levels increase and signs and symptoms recur, Octreotide Acetate injection therapy may be resumed. 2.3 Recommended Dosage and Monitoring for Carcinoid Tumors The recommended daily dosage of Octreotide Acetate injection during the first 2 weeks of therapy ranges from 100 to 600 mcg/day in two to four divided doses given subcutaneously (mean daily dosage is 300 mcg). In the clinical studies, the median daily maintenance dosage was approximately 450 mcg, but clinical and biochemical benefits were obtained in some patients with as little as 50 mcg, while others required doses up to 1500 mcg/day. However, experience with doses above 750 mcg/day is limited. Measurement of urinary 5-hydroxyindole acetic acid, plasma serotonin, plasma Substance P may be useful in monitoring the progress of therapy. 2.4 Recommended Dosage and Monitoring for Vasoactive Intestinal Peptide Tumors Daily dosages of 200 mcg to 300 mcg in two to four divided doses given subcutaneously are recommended during the initial 2 weeks of therapy (range, 150 mcg to 750 mcg) to control symptoms of the disease. On an individual basis, dosage may be adjusted to achieve a therapeutic response, but usually doses above 450 mcg/day are not required. Measurement of Plasma vasoactive intestinal peptide (VIP) may be useful in monitoring the progress of therapy. Discard unused portion."],"spl_product_data_elements":["Octreotide Acetate Octreotide Acetate OCTREOTIDE ACETATE OCTREOTIDE ACETIC ACID MANNITOL SODIUM ACETATE WATER Octreotide Acetate Octreotide Acetate OCTREOTIDE ACETATE OCTREOTIDE ACETIC ACID MANNITOL SODIUM ACETATE WATER Octreotide Acetate Octreotide Acetate OCTREOTIDE ACETATE OCTREOTIDE ACETIC ACID MANNITOL SODIUM ACETATE WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 50 mcg per mL, 100 mcg per mL, or 500 mcg per mL of octreotide (as acetate) as a clear solution in a single-dose vial. Injection: 50 mcg per mL, 100 mcg per mL, or 500 mcg per mL of octreotide (as acetate) in a single-dose vial. ( 3 )"],"recent_major_changes_table":["<table width=\"100%\"><colgroup><col width=\"79%\"/><col width=\"21%\"/></colgroup><tbody><tr><td>Warnings and Precautions, Steatorrhea and Malabsorption of Dietary Fats (<linkHtml href=\"#s5p5\">5.5</linkHtml>)</td><td align=\"center\">07/2024</td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Females and Males of Reproductive Potential : Advise premenopausal females of the potential for an unintended pregnancy. ( 8.3 ) 8.1 Pregnancy Risk Summary The limited data with octreotide acetate injection in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, no adverse developmental-effects were observed with IV administration of octreotide to pregnant rats and rabbits during organogenesis at doses 7- and 13-times, respectively the maximum recommended human dose (MRHD) of 1.5 mg/day based on body surface area (BSA). Transient growth retardation, with no impact on postnatal development, was observed in rat offspring from a pre- and post-natal study of octreotide at IV doses below the MRHD based on BSA ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data In postmarketing data, a limited number of exposed pregnancies have been reported in patients with acromegaly. Most women were exposed to octreotide during the first trimester of pregnancy at doses ranging from 100 to 300 mcg/day of octreotide acetate injection or 20 mg to 30 mg once a month of octreotide acetate for injectable suspension, however some women elected to continue octreotide therapy throughout pregnancy. In cases with a known outcome, no congenital malformations were reported. Animal Data In embryo-fetal development studies in rats and rabbits, pregnant animals received IV doses of octreotide up to 1 mg/kg/day during the period of organogenesis. A slight reduction in body weight gain was noted in pregnant rats at 0.1 and 1 mg/kg/day. There were no maternal effects in rabbits or embryo-fetal effects in either species up to the maximum dose tested. At 1 mg/kg/day in rats and rabbits, the dose multiple was approximately 7- and 13-times, respectively, at the highest recommended human dose of 1.5 mg/day based on BSA. In a pre- and post-natal development rat study at IV doses of 0.02-1 mg/kg/day, a transient growth retardation of the offspring was observed at all doses which was possibly a consequence of GH inhibition by octreotide. The doses attributed to the delayed growth are below the human dose of 1.5 mg/day, based on BSA. 8.2 Lactation Risk Summary There is no information available on the presence of octreotide acetate injection in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Studies show that octreotide administered subcutaneously passes into the milk of lactating rats; however, due to species-specific differences in lactation physiology, animal data may not reliably predict drug levels in human milk ( see Data ). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for octreotide acetate injection, and any potential adverse effects on the breastfed child from octreotide acetate injection or from the underlying maternal condition. Data Following a subcutaneous dose (1 mg/kg) of octreotide to lactating rats, transfer of octreotide into milk was observed at a low concentration compared to plasma (milk/plasma ratio of 0.009). 8.3 Females and Males of Reproductive Potential Discuss the potential for unintended pregnancy with premenopausal women as the therapeutic benefits of a reduction in GH levels and normalization of insulin-like growth factor 1 (IGF-1) concentration in acromegalic females treated with octreotide may lead to improved fertility. 8.4 Pediatric Use Safety and efficacy of octreotide acetate injection in the pediatric population have not been demonstrated. No formal controlled clinical trials have been performed to evaluate the safety and effectiveness of octreotide acetate injection in pediatric patients under age 6 years. In postmarketing reports, serious adverse events, including hypoxia, necrotizing enterocolitis, and death, have been reported with octreotide acetate injection use in children, most notably in children under 2 years of age. The relationship of these events to octreotide has not been established as the majority of these pediatric patients had serious underlying co-morbid conditions. The efficacy and safety of octreotide acetate injection using the octreotide acetate for injectable suspension formulation was examined in a single randomized, double-blind, placebo-controlled, 6 month pharmacokinetics study in 60 pediatric patients age 6 to 17 years with hypothalamic obesity resulting from cranial insult. The mean octreotide concentration after 6 doses of 40 mg octreotide acetate for injectable suspension administered by intramuscular (IM) injection every 4 weeks was approximately 3 ng/mL. Steady-state concentrations was achieved after 3 injections of a 40-mg dose. Mean body mass index (BMI) increased 0.1 kg/m 2 in octreotide acetate for injectable suspension-treated subjects compared to 0.0 kg/m 2 in saline control-treated subjects. Efficacy was not demonstrated. Diarrhea occurred in 11 of 30 (37%) patients treated with octreotide acetate for injectable suspension. No unexpected adverse events were observed. However, with octreotide acetate for injectable suspension at 40 mg once a month, the incidence of new cholelithiasis in this pediatric population (33%) was higher than that seen in other adult indications such as acromegaly (22%) or malignant carcinoid syndrome (24%), where octreotide acetate for injectable suspension was 10 mg to 30 mg once a month. 8.5 Geriatric Use Clinical studies of octreotide acetate injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. 8.6 Renal Impairment In patients with severe renal failure requiring dialysis, the half-life of octreotide acetate may be increased, necessitating adjustment of the maintenance dosage [see Clinical Pharmacology (12.3)] . 8.7 Hepatic Impairment-Cirrhotic Patients In patients with liver cirrhosis, the half-life of the drug may be increased, necessitating adjustment of the maintenance dosage [see Clinical Pharmacology (12.3)] ."],"package_label_principal_display_panel":["PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 50 mcg Vial Label NDC 71288- 566 -01 Rx Only Octreotide Acetate Injection 50 mcg per mL For Subcutaneous or Intravenous Use 1 mL Single-Dose Vial PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 50 mcg Vial Label","PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 50 mcg Carton NDC 71288- 566 -02 Rx Only Octreotide Acetate Injection 50 mcg per mL For Subcutaneous or Intravenous Use 10 x 1 mL Single-Dose Vials PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 50 mcg Carton","PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 100 mcg Vial Label NDC 71288- 567 -01 Rx Only Octreotide Acetate Injection 100 mcg per mL For Subcutaneous or Intravenous Use 1 mL Single-Dose Vial PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 100 mcg Vial Label","PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 100 mcg Carton NDC 71288- 567 -02 Rx Only Octreotide Acetate Injection 100 mcg per mL For Subcutaneous or Intravenous Use 10 x 1 mL Single-Dose Vials PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 100 mcg Carton","PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 500 mcg Vial Label NDC 71288- 568 -01 Rx Only Octreotide Acetate Injection 500 mcg per mL For Subcutaneous or Intravenous Use 1 mL Single-Dose Vial PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 500 mcg Vial Label","PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 500 mcg Carton NDC 71288- 568 -02 Rx Only Octreotide Acetate Injection 500 mcg per mL For Subcutaneous or Intravenous Use 10 x 1 mL Single-Dose Vials PACKAGE LABEL PRINCIPAL DISPLAY PANEL - Octreotide Acetate Injection 500 mcg Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies in laboratory animals have demonstrated no mutagenic potential of octreotide acetate injection. No carcinogenic potential was demonstrated in mice treated subcutaneously for 85 to 99 weeks at doses up to 2,000 mcg/kg/day (8 x the human exposure based on BSA). In a 116-week subcutaneous study in rats, a 27% and 12% incidence of injection-site sarcomas or squamous cell carcinomas was observed in males and females, respectively, at the highest dose level of 1,250 mcg/kg/day (10 x the human exposure based on BSA) compared to an incidence of 8% to 10% in the vehicle-control groups. The increased incidence of injection-site tumors was most probably caused by irritation and the high sensitivity of the rat to repeated subcutaneous injections at the same site. Rotating injection sites would prevent chronic irritation in humans. There have been no reports of injection-site tumors in patients treated with octreotide acetate for up to 5 years. There was also a 15% incidence of uterine adenocarcinomas in the 1,250 mcg/kg/day females compared to 7% in the saline-control females and 0% in the vehicle-control females. The presence of endometritis coupled with the absence of corpora lutea, the reduction in mammary fibroadenomas, and the presence of uterine dilatation suggest that the uterine tumors were associated with estrogen dominance in the aged female rats which does not occur in humans. Octreotide did not impair fertility in rats at doses up to 1,000 mcg/kg/day, which represents 7-times the human exposure based on BSA."]},"tags":[{"label":"Somatostatin Analog","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Somatostatin receptor type 2","category":"target"},{"label":"SSTR2","category":"gene"},{"label":"SSTR5","category":"gene"},{"label":"SSTR3","category":"gene"},{"label":"H01CB02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Subcutaneous","category":"route"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acromegaly","category":"indication"},{"label":"Carcinoid syndrome","category":"indication"},{"label":"Congenital hyperinsulinism","category":"indication"},{"label":"Diarrhea from Pancreatic VIPoma","category":"indication"},{"label":"Novartis","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Hormonal","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":5275.045,"date":"","count":1544,"signal":"Needle issue","source":"DrugCentral FAERS","actionTaken":"Reported 1,544 times (LLR=5275)"},{"llr":2232.062,"date":"","count":1331,"signal":"Blood pressure systolic increased","source":"DrugCentral FAERS","actionTaken":"Reported 1,331 times (LLR=2232)"},{"llr":1944.279,"date":"","count":918,"signal":"Body temperature decreased","source":"DrugCentral FAERS","actionTaken":"Reported 918 times (LLR=1944)"},{"llr":1415.642,"date":"","count":1617,"signal":"Blood pressure increased","source":"DrugCentral FAERS","actionTaken":"Reported 1,617 times (LLR=1416)"},{"llr":1413.868,"date":"","count":1291,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 1,291 times (LLR=1414)"},{"llr":1370.014,"date":"","count":1249,"signal":"Injection site pain","source":"DrugCentral FAERS","actionTaken":"Reported 1,249 times (LLR=1370)"},{"llr":1230.824,"date":"","count":1248,"signal":"Inappropriate schedule of product administration","source":"DrugCentral FAERS","actionTaken":"Reported 1,248 times (LLR=1231)"},{"llr":1089.358,"date":"","count":532,"signal":"Injection site mass","source":"DrugCentral FAERS","actionTaken":"Reported 532 times (LLR=1089)"},{"llr":879.558,"date":"","count":348,"signal":"Syringe issue","source":"DrugCentral FAERS","actionTaken":"Reported 348 times (LLR=880)"},{"llr":780.686,"date":"","count":508,"signal":"Blood pressure diastolic decreased","source":"DrugCentral FAERS","actionTaken":"Reported 508 times (LLR=781)"},{"llr":688.694,"date":"","count":455,"signal":"Metastases to liver","source":"DrugCentral FAERS","actionTaken":"Reported 455 times (LLR=689)"},{"llr":656.333,"date":"","count":648,"signal":"Heart rate decreased","source":"DrugCentral FAERS","actionTaken":"Reported 648 times (LLR=656)"},{"llr":614.592,"date":"","count":151,"signal":"Blood growth hormone increased","source":"DrugCentral FAERS","actionTaken":"Reported 151 times (LLR=615)"},{"llr":426.85,"date":"","count":406,"signal":"Flatulence","source":"DrugCentral FAERS","actionTaken":"Reported 406 times (LLR=427)"},{"llr":409.635,"date":"","count":1263,"signal":"Abdominal pain","source":"DrugCentral FAERS","actionTaken":"Reported 1,263 times (LLR=410)"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"34% to 61%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"34% to 61%","severity":"common","_validated":true},{"effect":"Abdominal discomfort","drugRate":"34% to 61%","severity":"common","_validated":true},{"effect":"Loose stools","drugRate":"34% to 61%","severity":"common","_validated":true},{"effect":"Sinus bradycardia","drugRate":"25%","severity":"serious","_validated":true},{"effect":"Conduction abnormalities","drugRate":"10%","severity":"common","_validated":true},{"effect":"Arrhythmias","drugRate":"9%","severity":"common","_validated":true},{"effect":"Hypoglycemia","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Hyperglycemia","drugRate":"16%","severity":"common","_validated":true},{"effect":"Biochemical hypothyroidism","drugRate":"12%","severity":"serious","_validated":true},{"effect":"Goiter","drugRate":"6%","severity":"serious","_validated":true},{"effect":"Pain on injection","drugRate":"7.7%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"6%","severity":"mild","_validated":true},{"effect":"Dizziness","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"5% to 10%","severity":"mild","_validated":true},{"effect":"Flatulence","drugRate":"5% to 10%","severity":"mild","_validated":true},{"effect":"Abnormal stools","drugRate":"5% to 10%","severity":"mild","_validated":true},{"effect":"Abdominal distention","drugRate":"5% to 10%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"5% to 10%","severity":"mild","_validated":true},{"effect":"Fatigue","drugRate":"reported","severity":"unknown"},{"effect":"Weakness","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Joint pain","drugRate":"reported","severity":"unknown"},{"effect":"Backache","drugRate":"reported","severity":"unknown"},{"effect":"Urinary tract infection","drugRate":"reported","severity":"unknown"},{"effect":"Cold symptoms","drugRate":"reported","severity":"unknown"},{"effect":"Flu symptoms","drugRate":"reported","severity":"unknown"},{"effect":"Injection site hematoma","drugRate":"reported","severity":"unknown"},{"effect":"Bruise","drugRate":"reported","severity":"unknown"},{"effect":"Edema","drugRate":"reported","severity":"unknown"}],"contraindications":["Bradycardia","Calculus in biliary tract","Chronic heart failure","Cirrhosis of liver","Cobalamin deficiency","Conduction disorder of the heart","Diabetes mellitus","Disorder of gallbladder","Hyperglycemia","Hypoglycemic disorder","Hypothyroidism","Intestinal obstruction","Renal failure syndrome"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies of octreotide use in pregnant women. Reproduction studies have been performed in rats and rabbits at doses up to 16 times the highest recommended human dose based on body surface area and revealed no evidence of harm to the fetus due to octreotide. However, because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. In postmarketing data, limited number of exposures were reported, but no adverse effects on the fetus were observed. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.","Geriatric use":"Clinical studies of octreotide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.","Paediatric use":"Safety and efficacy of octreotide acetate injection in the pediatric population have not been demonstrated.No formal controlled clinical trials have been performed to evaluate the safety and effectiveness of octreotide acetate injection in pediatric patients under age 2 years. In postmarketing reports, serious adverse events, including hypoxia, necrotizing enterocolitis, and death, have been reported with octreotide acetate use in children, most notably in children under 1 year of age."}},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-12-18","unitCost":"$6.5424/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,355","description":"OCTREOTIDE 1,000 MCG/5 ML VIAL","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OCTREOTIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:41:52.761738+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Octreotide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:41:59.624224+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:41:58.276838+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:41:52.834147+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OCTREOTIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:41:58.549372+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:50.173802+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:50.173826+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1680/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:41:59.273778+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA075957","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:41:50.173830+00:00"}},"allNames":"sandostatin","offLabel":[],"synonyms":["octreotide","longastatin","octreotide acetate","sandostatin","SMS-201-995","sandostatine"],"timeline":[{"date":"1988-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from NOVARTIS to Novartis"},{"date":"1988-10-21","type":"positive","source":"DrugCentral","milestone":"FDA approval (Novartis)"},{"date":"1998-11-25","type":"positive","source":"FDA Orange Book","milestone":"Sandostatin Lar approved — EQ 10MG BASE/VIAL"},{"date":"2005-04-08","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"},{"date":"2020-06-26","type":"positive","source":"FDA Orange Book","milestone":"Mycapssa approved — EQ 20MG BASE"},{"date":"2020-08-21","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Novartis Pharma K.K., Sandoz K.K.)"},{"date":"2022-12-02","type":"positive","source":"DrugCentral","milestone":"EMA approval (Amryt Pharmaceuticals Dac)"},{"date":"2024-09-27","type":"positive","source":"FDA Orange Book","milestone":"Bynfezia Pen approved — EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)"}],"aiSummary":"Sandostatin (Octreotide) is a somatostatin analog developed by Novartis, targeting the somatostatin receptor type 2. It is a small molecule drug class, approved by the FDA in 1988 for various indications including acromegaly, carcinoid syndrome, and diarrhea from pancreatic VIPoma. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its short half-life of 1.7 hours and low bioavailability of 2%. Sandostatin is commercially available, with no active Orange Book patents.","approvals":[{"date":"1988-10-21","orphan":true,"company":"NOVARTIS","regulator":"FDA"},{"date":"2020-08-21","orphan":false,"company":"Novartis Pharma K.K., Sandoz K.K.","regulator":"PMDA"},{"date":"2022-12-02","orphan":true,"company":"AMRYT PHARMACEUTICALS DAC","regulator":"EMA"}],"brandName":"Sandostatin","ecosystem":[{"indication":"Acromegaly","otherDrugs":[{"name":"bromocriptine","slug":"bromocriptine","company":"Us Pharms Holdings I"},{"name":"lanreotide","slug":"lanreotide","company":"Ipsen Pharma"},{"name":"pegvisomant","slug":"pegvisomant","company":"Pharmacia And Upjohn"}],"globalPrevalence":1100000},{"indication":"Carcinoid syndrome","otherDrugs":[],"globalPrevalence":null},{"indication":"Congenital hyperinsulinism","otherDrugs":[],"globalPrevalence":null},{"indication":"Diarrhea from Pancreatic VIPoma","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Somatostatin receptor type 2","novelty":"Follow-on","targets":[{"gene":"SSTR2","source":"DrugCentral","target":"Somatostatin receptor type 2","protein":"Somatostatin receptor type 2"},{"gene":"SSTR5","source":"DrugCentral","target":"Somatostatin receptor type 5","protein":"Somatostatin receptor type 5"},{"gene":"SSTR3","source":"DrugCentral","target":"Somatostatin receptor type 3","protein":"Somatostatin receptor type 3"},{"gene":"OPRM1","source":"DrugCentral","target":"Mu-type opioid receptor","protein":"Mu-type opioid receptor"},{"gene":"SSTR1","source":"DrugCentral","target":"Somatostatin receptor type 1","protein":"Somatostatin receptor type 1"},{"gene":"SSTR4","source":"DrugCentral","target":"Somatostatin receptor type 4","protein":"Somatostatin receptor type 4"}],"moaClass":"Somatostatin Receptor Agonists","modality":"Peptide","drugClass":"Somatostatin Analog","explanation":"Octreotide exerts pharmacologic actions similar to the natural hormone somatostatin, but is more potent inhibitor of GH, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH), decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide.","oneSentence":"Sandostatin works by mimicking the natural hormone somatostatin to inhibit the release of various hormones and growth factors.","technicalDetail":"Sandostatin binds to somatostatin receptor type 2 (SSTR2), a G protein-coupled receptor, which triggers a signaling cascade that inhibits the release of hormones such as growth hormone, insulin, and gastrin, thereby exerting its therapeutic effects."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Octreotide","title":"Octreotide","extract":"Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 and binds predominantly to the somatostatin receptors SSTR2 and SSTR5.","wiki_history":"==History==\nOctreotide acetate was approved for use in the United States in 1988.\n* the reduction of growth hormone and insulin-like growth factor 1 (somatomedin C) in adults with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses\n* severe diarrhea/flushing episodes associated with metastatic carcinoid tumors in adults\n* profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas) in adults","wiki_society_and_culture":"== Society and culture ==\n=== Legal status ===\nIn September 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Mycapssa, intended for the treatment of adults with acromegaly. Mycapssa was approved for medical use in the European Union in December 2022.\n\nIn April 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Oczyesa, intended for the maintenance treatment of adults with acromegaly. Oczyesa was authorized for medical use in the European Union in June 2025."},"commercial":{"launchDate":"1988","revenueYear":2025,"_launchSource":"DrugCentral (FDA 1988-10-21, NOVARTIS)","annualRevenue":305,"revenueSource":"SEC 8-K Novartis (2024-10-29)","revenueCurrency":"USD","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:47.291579","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1980","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OCTREOTIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OCTREOTIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Octreotide","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T13:05:14.772565","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:42:02.860752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"lanreotide","drugSlug":"lanreotide","fdaApproval":"2007-08-30","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"pasireotide","drugSlug":"pasireotide","fdaApproval":"2012-12-14","patentExpiry":"Oct 25, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"octreotide","indications":{"approved":[{"name":"Acromegaly","source":"DrugCentral","snomedId":74107003,"regulator":"FDA","globalPrevalence":1100000,"prevalenceMethod":"ai-extracted","prevalenceSource":"Eur J Endocrinol, 2021 (PMID:34061771)"},{"name":"Carcinoid syndrome","source":"DrugCentral","snomedId":35868009,"regulator":"FDA"},{"name":"Congenital hyperinsulinism","source":"DrugCentral","snomedId":360339005,"regulator":"FDA"},{"name":"Diarrhea from Pancreatic VIPoma","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Bleeding esophageal varices","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":279,"evidenceLevel":"strong"},{"name":"Carcinoid crisis","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":83,"evidenceLevel":"strong"},{"name":"Chemotherapy-Induced Diarrhea","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":39,"evidenceLevel":"moderate"},{"name":"Chylothorax","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":315,"evidenceLevel":"strong"},{"name":"Gastrointestinal fistula","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":315,"evidenceLevel":"strong"},{"name":"Insulinoma","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":346,"evidenceLevel":"strong"},{"name":"Irritable bowel syndrome","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":30,"evidenceLevel":"moderate"},{"name":"Islet cell hyperplasia","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":58,"evidenceLevel":"strong"},{"name":"Non-infective diarrhea","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Pancreatic fistula","source":"DrugCentral","drugName":"OCTREOTIDE","evidenceCount":281,"evidenceLevel":"strong"},{"name":"Postgastric surgery syndrome","source":"DrugCentral","drugName":"OCTREOTIDE"},{"name":"Short bowel syndrome","source":"DrugCentral","drugName":"OCTREOTIDE"}],"pipeline":[]},"currentOwner":"Novartis","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"lanreotide","brandName":"lanreotide","genericName":"lanreotide","approvalYear":"2007","relationship":"same-class"},{"drugId":"pasireotide","brandName":"pasireotide","genericName":"pasireotide","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03252353","phase":"PHASE3","title":"Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly","status":"UNKNOWN","sponsor":"Chiasma, Inc.","isPivotal":true,"startDate":"2017-09-01","conditions":["Acromegaly"],"enrollment":56,"completionDate":"2022-05"},{"nctId":"NCT02019706","phase":"PHASE2","title":"Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-12","conditions":["ACTH","Cushing's Syndrome"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":["Colorectal Neuroendocrine Tumor G1","Gastric Neuroendocrine Tumor G1","Neuroendocrine Neoplasm","Neuroendocrine Tumor","Neuroendocrine Tumor G2"],"enrollment":427,"completionDate":"2027-01-31"},{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":["Hoffa's Fat Pad Impingement"],"enrollment":62,"completionDate":"2028-01-02"},{"nctId":"NCT05361668","phase":"PHASE2","title":"Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2022-04-22","conditions":["Carcinoid Syndrome","Carcinoid","Carcinoid Tumor","Carcinoid Tumor of Ileum","Carcinoid Tumor of Cecum","Carcinoid Syndrome Diarrhea","Carcinoid Intestine Tumor","Carcinoid Tumor of Liver","Carcinoid Tumor of Pancreas"],"enrollment":36,"completionDate":"2026-02-24"},{"nctId":"NCT07479784","phase":"PHASE3","title":"Octreotide Microspheres for Preventing Pancreatic Fistula","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-04-01","conditions":["Pancreatic Fistula"],"enrollment":230,"completionDate":"2028-12-31"},{"nctId":"NCT07460908","phase":"NA","title":"Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2025-05-01","conditions":["Hepatorenal Syndrome"],"enrollment":60,"completionDate":"2025-10-30"},{"nctId":"NCT07087054","phase":"PHASE3","title":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-11-19","conditions":["Carcinoid Syndrome","Carcinoid","Carcinoid Tumor","Carcinoid Tumor of Ileum","Carcinoid Tumor of Cecum","Carcinoid Tumor of Liver","Carcinoid Tumor of Pancreas","Carcinoid Syndrome Diarrhea","Carcinoid Intestine Tumor"],"enrollment":141,"completionDate":"2030-01"},{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":["Somatostatin Receptor Positive (SSTR+)","Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)"],"enrollment":240,"completionDate":"2034-01-05"},{"nctId":"NCT05918302","phase":"PHASE3","title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-10-27","conditions":["Neuroendocrine Tumors","Lung Neuroendocrine Neoplasm","Thymus Neoplasms"],"enrollment":120,"completionDate":"2028-07"},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":["Acromegaly"],"enrollment":119,"completionDate":"2029-03"},{"nctId":"NCT07403604","phase":"PHASE1","title":"Effect of Insulin Lowering on Lipogenesis","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-04","conditions":["Hyperinsulinemia","Insulin Resistance","Non-Alcoholic Fatty Liver Disease","Prediabetic State","Obesity"],"enrollment":25,"completionDate":"2029-06"},{"nctId":"NCT06558422","phase":"PHASE1","title":"Human Models of Selective Insulin Resistance: Pancreatic Clamp","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2027-01-01","conditions":["Insulin Resistance","Hyperinsulinemia","Metabolic Dysfunction Associated Steatotic Liver Disease","Non-Alcoholic Fatty Liver Disease","Prediabetic State","Obesity"],"enrollment":36,"completionDate":"2029-02-28"},{"nctId":"NCT03879694","phase":"PHASE1","title":"Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-17","conditions":["Lung Atypical Carcinoid Tumor","Lung Typical Carcinoid Tumor","Metastatic Pancreatic Neuroendocrine Tumor"],"enrollment":19,"completionDate":"2025-03-14"},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":["Gastro-enteropancreatic Neuroendocrine Tumor"],"enrollment":226,"completionDate":"2027-10-29"},{"nctId":"NCT06865677","phase":"PHASE2","title":"Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-09","conditions":["Recurrent Platinum Resistant Epithelial Ovarian Carcinoma","Recurrent Epithelial Endometrial Carcinoma","Recurrent Epithelial Cervical Carcinoma"],"enrollment":2,"completionDate":"2025-07-01"},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":["GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET"],"enrollment":288,"completionDate":"2028-07"},{"nctId":"NCT05724134","phase":"PHASE1","title":"Pancreatic Clamp in NAFLD","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-08-29","conditions":["Insulin Resistance","Prediabetic State","Hyperinsulinemia","Non-Alcoholic Fatty Liver Disease","Obesity"],"enrollment":18,"completionDate":"2025-09-24"},{"nctId":"NCT07102056","phase":"","title":"18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-01-01","conditions":["Neuroendocrine Tumors"],"enrollment":152,"completionDate":"2027-12-31"},{"nctId":"NCT04125836","phase":"PHASE3","title":"A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-10-10","conditions":["Acromegaly"],"enrollment":135,"completionDate":"2025-04-24"},{"nctId":"NCT07262957","phase":"PHASE4","title":"Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-09-01","conditions":["Pancreas Head Cancer","Pancreas Adenocarcinoma","IPMN, Pancreatic","Cholangio Carcinoma","Ampulla of Vater Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Duodenal Carcinoma","Mucinous Cystic Neoplasm","Neuro Endocrine Tumours","Pancreatitis"],"enrollment":400,"completionDate":"2027-12-01"},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":["Somatostatin Receptor Positive","NETs","Lymphoma","Solid Tumor","CNS Tumors","Rhabdomyosarcoma","Peripheral Primitive Neuroectodermal Tumor","GIST"],"enrollment":20,"completionDate":"2034-04"},{"nctId":"NCT05281328","phase":"PHASE2,PHASE3","title":"A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2022-06-28","conditions":["Polycystic Liver Disease"],"enrollment":71,"completionDate":"2027-08"},{"nctId":"NCT06592261","phase":"PHASE1","title":"Graded Insulin Suppression Test P&F","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-09-16","conditions":["Insulin Resistance","Hyperinsulinemia","Obesity","Healthy"],"enrollment":15,"completionDate":"2026-08"},{"nctId":"NCT03624517","phase":"PHASE4","title":"Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2018-09-19","conditions":["Esophageal Varices","Liver Cirrhoses","Bleeding Esophageal Varices","Upper Gastrointestinal Bleeding"],"enrollment":34,"completionDate":"2024-12-01"},{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":["Acromegaly","GEP-NET"],"enrollment":19,"completionDate":"2024-12-03"},{"nctId":"NCT05050942","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2021-10-22","conditions":["Gastro-enteropancreatic Neuroendocrine Tumor"],"enrollment":332,"completionDate":"2028-07"},{"nctId":"NCT00262470","phase":"PHASE1,PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":["Tachycardia","Chronic Orthostatic Intolerance"],"enrollment":150,"completionDate":"2029-12"},{"nctId":"NCT06881888","phase":"PHASE1","title":"Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-08-31","conditions":["Diabetic Macular Edema"],"enrollment":60,"completionDate":"2027-12"},{"nctId":"NCT07195500","phase":"","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-12-25","conditions":["Neuroblastoma","Pheochromocytoma","Paraganglioma"],"enrollment":30,"completionDate":"2028-06-30"},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":["Recurrent Meningioma"],"enrollment":136,"completionDate":"2028-12-22"},{"nctId":"NCT03000946","phase":"PHASE3","title":"Prevention of Postoperative Pancreatic Fistula by Somatostatin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-15","conditions":["Pancreatic Surgery"],"enrollment":655,"completionDate":"2021-02-09"},{"nctId":"NCT04919226","phase":"PHASE3","title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2021-12-21","conditions":["Neuroendocrine Tumors"],"enrollment":259,"completionDate":"2027-09"},{"nctId":"NCT05387603","phase":"PHASE3","title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2022-11-01","conditions":["Neuroendocrine Tumors"],"enrollment":300,"completionDate":"2026-10-01"},{"nctId":"NCT07165886","phase":"PHASE2,PHASE3","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-29","conditions":["Gastroenteropancreatic Neuroendocrine Tumors"],"enrollment":243,"completionDate":"2028-08-29"},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":["Neuroendocrine Tumors"],"enrollment":196,"completionDate":"2028-12"},{"nctId":"NCT06193616","phase":"","title":"Outcome of ADPKD With Octreotide LAR","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2024-02-12","conditions":["Autosomal Dominant Polycystic Kidney"],"enrollment":70,"completionDate":"2025-12"},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":["Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)"],"enrollment":166,"completionDate":"2029-01"},{"nctId":"NCT06345079","phase":"PHASE2","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-10-14","conditions":["Neuroendocrine Tumors"],"enrollment":78,"completionDate":"2028-06"},{"nctId":"NCT07104487","phase":"PHASE2","title":"[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-03-18","conditions":["Stroke (CVA) or TIA","Carotid Artery Plaque","Atherosclerosis Cardiovascular Disease","Carotid Arteriosclerosis"],"enrollment":24,"completionDate":"2029-09"},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":["NETS Ga68 Lu177"],"enrollment":184,"completionDate":"2027-02-24"},{"nctId":"NCT01673906","phase":"PHASE2","title":"68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2012-08","conditions":["Neuroendocrine Tumours"],"enrollment":142,"completionDate":"2016-07-05"},{"nctId":"NCT03466216","phase":"PHASE1","title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","status":"TERMINATED","sponsor":"Orano Med LLC","startDate":"2018-02-05","conditions":["Neuroendocrine Tumor"],"enrollment":33,"completionDate":"2023-04-06"},{"nctId":"NCT05153772","phase":"PHASE2","title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orano Med LLC","startDate":"2021-12-21","conditions":["Neuroendocrine Tumors"],"enrollment":69,"completionDate":"2028-10"},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":["Neuroendocrine Tumors"],"enrollment":309,"completionDate":"2029-11"},{"nctId":"NCT06974344","phase":"PHASE4","title":"Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","status":"NOT_YET_RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2025-06-01","conditions":["Small-for-Size Syndrome"],"enrollment":80,"completionDate":"2030-09-01"},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":["Neuroendocrine Tumors"],"enrollment":51,"completionDate":"2023-04-10"},{"nctId":"NCT00113360","phase":"PHASE2","title":"RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-01","conditions":["Neuroendocrine Carcinoma","Islet Cell Carcinoma"],"enrollment":67,"completionDate":"2009-07"},{"nctId":"NCT04997317","phase":"PHASE1,PHASE2","title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-21","conditions":["Meningioma"],"enrollment":18,"completionDate":"2026-12-31"},{"nctId":"NCT06881628","phase":"PHASE4","title":"Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-02","conditions":["Upper Gastrointestinal Bleeding (UGIB)","Variceal Bleeding","Cirrhosis"],"enrollment":194,"completionDate":"2025-12-30"},{"nctId":"NCT03792555","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2019-03-11","conditions":["Acromegaly"],"enrollment":13,"completionDate":"2020-08-12"},{"nctId":"NCT02457156","phase":"PHASE3","title":"Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2015-04-23","conditions":["Pancreatic Cancer"],"enrollment":295,"completionDate":"2019-01-31"},{"nctId":"NCT00463983","phase":"PHASE1,PHASE2","title":"Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-10","conditions":["Idiopathic Pulmonary Fibrosis"],"enrollment":25,"completionDate":"2012-01"},{"nctId":"NCT02795858","phase":"PHASE2","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-06-14","conditions":["Carcinoid Tumors"],"enrollment":43,"completionDate":"2023-12-31"},{"nctId":"NCT02691078","phase":"PHASE2","title":"Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Latin American Cooperative Oncology Group","startDate":"2016-07","conditions":["Neuroendocrine Tumors"],"enrollment":15,"completionDate":"2018-01-10"},{"nctId":"NCT02736448","phase":"PHASE2","title":"177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05","conditions":["Gastro-entero-pancreatic Neuroendocrine Tumors"],"enrollment":35,"completionDate":"2023-04-30"},{"nctId":"NCT06753630","phase":"NA","title":"Polydeoxyribonucleotide for Elbow Lateral Epicondylitis","status":"COMPLETED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2014-11-20","conditions":["Lateral Epicondylitis","Extracorporeal Shockwave Therapy","Muscle Strengthening"],"enrollment":48,"completionDate":"2016-11-30"},{"nctId":"NCT04917484","phase":"PHASE2","title":"Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients","status":"RECRUITING","sponsor":"Tine Gregersen, MD","startDate":"2020-02-01","conditions":["Neuroendocrine Neoplasm"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT05833217","phase":"NA","title":"Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-06-06","conditions":["Long COVID","Insulin Resistance","Insulin Sensitivity"],"enrollment":55,"completionDate":"2025-12-31"},{"nctId":"NCT04871204","phase":"PHASE2","title":"Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer","status":"COMPLETED","sponsor":"Fredrik Klevebro","startDate":"2021-06-16","conditions":["Esophageal Cancer","Gastric Cancer"],"enrollment":20,"completionDate":"2024-02-21"},{"nctId":"NCT06505395","phase":"PHASE2","title":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-07-30","conditions":["Gastrointestinal Neuroendocrine Pancreatic Tumor"],"enrollment":90,"completionDate":"2028-08-01"},{"nctId":"NCT06045260","phase":"PHASE2","title":"\"Receptor Radionuclide Therapy With 177Lu-DOTATOC","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2023-09-13","conditions":["Neuroendocrine Tumors","Paraganglioma","Pheochromocytoma"],"enrollment":100,"completionDate":"2027-01"},{"nctId":"NCT01424241","phase":"PHASE4","title":"Effects of Sandostatin LAR® in Acromegaly","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-10","conditions":["Acromegaly"],"enrollment":21,"completionDate":"2014-01"},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":["Insulin Resistance","Prediabetic State","Non-Alcoholic Fatty Liver Disease","Overweight and Obesity"],"enrollment":0,"completionDate":"2026-03-31"},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":["Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":270,"completionDate":"2034-04"},{"nctId":"NCT04076462","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-08-19","conditions":["Acromegaly"],"enrollment":72,"completionDate":"2023-05-02"},{"nctId":"NCT05359146","phase":"EARLY_PHASE1","title":"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-28","conditions":["Neuroendocrine Neoplasia's (NENs)","Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)"],"enrollment":16,"completionDate":"2025-12"},{"nctId":"NCT01070758","phase":"PHASE4","title":"Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-02","conditions":["Congenital Hyperinsulinism"],"enrollment":3,"completionDate":"2015-02"},{"nctId":"NCT05749289","phase":"PHASE2,PHASE3","title":"Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-12-20","conditions":["Neuroendocrine Tumor"],"enrollment":400,"completionDate":"2025-12-20"},{"nctId":"NCT03377660","phase":"","title":"Resection of the Esophagus and Subsequent Weight Loss","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2018-01-01","conditions":["Esophageal Cancer","Weight Gain","Eating Behavior","Food Reward"],"enrollment":30,"completionDate":"2023-06-01"},{"nctId":"NCT06300216","phase":"","title":"A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-03-26","conditions":["Neuroendocrine Tumors"],"enrollment":500,"completionDate":"2028-05-26"},{"nctId":"NCT04048707","phase":"PHASE2","title":"Angiotensin 2 for Hepatorenal Syndrome","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-07-01","conditions":["Hepatorenal Syndrome","Cirrhosis","Kidney Failure, Acute"],"enrollment":0,"completionDate":"2023-07-01"},{"nctId":"NCT03179995","phase":"PHASE2","title":"Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2017-07-07","conditions":["Major Liver Resection"],"enrollment":23,"completionDate":"2020-02-12"},{"nctId":"NCT06254235","phase":"PHASE1","title":"Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-06-16","conditions":["Healthy Volunteers"],"enrollment":240,"completionDate":"2021-12-01"},{"nctId":"NCT06240039","phase":"NA","title":"Direct Versus Indirect Effect of Amino Acids on Hepatokines","status":"NOT_YET_RECRUITING","sponsor":"University of Copenhagen","startDate":"2024-02","conditions":["Non-Alcoholic Fatty Liver Disease","Obesity"],"enrollment":30,"completionDate":"2026-12"},{"nctId":"NCT03724409","phase":"EARLY_PHASE1","title":"Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases","status":"TERMINATED","sponsor":"Sandeep Laroia","startDate":"2018-10-11","conditions":["Neuroendocrine Tumors"],"enrollment":3,"completionDate":"2023-05-23"},{"nctId":"NCT02385617","phase":"NA","title":"Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2014-01","conditions":["Esophageal Neoplasms","Stomach Neoplasms","Weight Loss","Malnutrition"],"enrollment":20,"completionDate":"2017-12"},{"nctId":"NCT02381249","phase":"NA","title":"The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2015-03","conditions":["Esophageal Neoplasms","Stomach Neoplasms","Weight Loss","Malnutrition","Pancreatic Neoplasms","Duodenal Neoplasms"],"enrollment":40,"completionDate":"2018-03"},{"nctId":"NCT06080204","phase":"NA","title":"Real-world Study on Adjuvant Octreotide Therapy in pNETs","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2008-03","conditions":["Pancreatic Neuroendocrine Tumor G2"],"enrollment":411,"completionDate":"2020-04"},{"nctId":"NCT06085976","phase":"PHASE2","title":"Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2023-08-14","conditions":["Hepatic Carcinoma","Hepatic Metastasis"],"enrollment":62,"completionDate":"2025-11-30"},{"nctId":"NCT05761431","phase":"PHASE1","title":"A Single-dose Study of Octreotide Injection in Healthy Adult Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-03-02","conditions":["Acromegaly"],"enrollment":56,"completionDate":"2023-06-28"},{"nctId":"NCT06062719","phase":"PHASE2,PHASE3","title":"Role of Octreotide in Non Variceal Bleeding","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2023-08-23","conditions":["Non-variceal Gastrointestinal Bleeding"],"enrollment":56,"completionDate":"2025-01"},{"nctId":"NCT03044977","phase":"EARLY_PHASE1","title":"Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bushnell","startDate":"2017-05-07","conditions":["Neuroendocrine Tumor, Malignant","Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting"],"enrollment":20,"completionDate":"2027-12"},{"nctId":"NCT05884255","phase":"PHASE3","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-06","conditions":["Advanced Gastroenteropancreatic Neuroendocrine Tumor"],"enrollment":220,"completionDate":"2030-10"},{"nctId":"NCT00427349","phase":"PHASE2","title":"AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2008-11-07","conditions":["Gastrointestinal Carcinoid Tumor","Islet Cell Tumor","Neoplastic Syndrome"],"enrollment":46,"completionDate":"2015-04"},{"nctId":"NCT00003057","phase":"PHASE3","title":"Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-03-26","conditions":["Colorectal Cancer","Diarrhea"],"enrollment":500,"completionDate":""},{"nctId":"NCT00003283","phase":"PHASE2","title":"Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1998-10-13","conditions":["Thymoma and Thymic Carcinoma"],"enrollment":38,"completionDate":""},{"nctId":"NCT05894486","phase":"PHASE2","title":"Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2023-06-05","conditions":["Neuroendocrine Tumors"],"enrollment":40,"completionDate":"2026-06-05"},{"nctId":"NCT02333565","phase":"PHASE2","title":"Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2015-01-22","conditions":["Recurrent Meningiomas","Resistant Meningiomas"],"enrollment":20,"completionDate":"2023-05-24"},{"nctId":"NCT02384122","phase":"PHASE3","title":"Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-09","conditions":["Angiodysplasia","Vascular Malformations","Gastrointestinal Hemorrhage","Anemia"],"enrollment":62,"completionDate":"2023-05"},{"nctId":"NCT04941911","phase":"PHASE2","title":"A Feasibility Study of Octreotide Infusion During Liver Transplant.","status":"UNKNOWN","sponsor":"University College, London","startDate":"2022-05-27","conditions":["Liver Transplantation","Renal Failure"],"enrollment":30,"completionDate":"2024-01-31"},{"nctId":"NCT05683444","phase":"EARLY_PHASE1","title":"Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-07-01","conditions":["Lymphatic Diseases","Chylothorax"],"enrollment":16,"completionDate":"2021-03-26"},{"nctId":"NCT03967249","phase":"PHASE2","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-07-25","conditions":["Acromegaly"],"enrollment":39,"completionDate":"2022-07-07"},{"nctId":"NCT04276597","phase":"PHASE2","title":"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.","status":"WITHDRAWN","sponsor":"Excel Diagnostics and Nuclear Oncology Center","startDate":"2020-03-04","conditions":["Pulmonary Neuroendocrine Neoplasm","Pheochromocytoma","Paraganglioma","Thymus Carcinoid","Unknown Primary Tumors","Neuroendocrine Tumors","Neuroendocrine Skin Carcinoma","Neuroendocrine Breast Tumor","Neuroendocrine Carcinoma Metastatic","Neuroendocrine Neoplasm of Ovary"],"enrollment":0,"completionDate":"2021-07-15"},{"nctId":"NCT02335580","phase":"","title":"Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2014-12","conditions":["Liver Cirrhosis","Portal Vein","Venous Thrombosis","Varicose Veins","Hemorrhage"],"enrollment":475,"completionDate":"2022-12"},{"nctId":"NCT04915144","phase":"PHASE2","title":"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs","status":"WITHDRAWN","sponsor":"British Columbia Cancer Agency","startDate":"2023-01-15","conditions":["Neuroendocrine Tumors","Carcinoid Tumor","Pulmonary Carcinoid Tumor","Gastroenteropancreatic Neuroendocrine Tumor","Vipoma","Insulinoma","Gastrinoma"],"enrollment":0,"completionDate":"2031-12-31"},{"nctId":"NCT03273712","phase":"PHASE2","title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2017-09-29","conditions":["Neuroendocrine Tumors","Meningioma","Neuroblastoma","Medulloblastoma"],"enrollment":39,"completionDate":"2020-05-27"},{"nctId":"NCT03891849","phase":"NA","title":"Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-09-01","conditions":["Haemorrhagic Shock","Variceal Hemorrhage"],"enrollment":0,"completionDate":"2023-05"},{"nctId":"NCT05682209","phase":"PHASE4","title":"The Effect of Octreotide on Wound Drainage After Mastectomy","status":"COMPLETED","sponsor":"Ikechukwu Bartholomew Ulasi","startDate":"2020-12-18","conditions":["Seroma Following Procedure"],"enrollment":41,"completionDate":"2021-12-02"},{"nctId":"NCT01538966","phase":"NA","title":"Acromegaly Combination Treatment Study","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03-29","conditions":["Acromegaly"],"enrollment":76,"completionDate":"2022-05-20"},{"nctId":"NCT01613495","phase":"NA","title":"Ghrelin Suppression by Octreotide in Prader-Willi","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-08","conditions":["Prader Willis Syndrome"],"enrollment":2,"completionDate":"2024-11"}],"_emaApprovals":[{"date":"2022-12-02","status":"Authorised","company":"AMRYT PHARMACEUTICALS DAC"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT03252353"],"administration":{"route":"Intravenous","formulation":"Capsule, Injection","formulations":[{"form":"CAPSULE, DELAYED RELEASE","route":"ORAL","productName":"Mycapssa"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Octreotide Acetate"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Octreotide acetate"},{"form":"INJECTION","route":"SUBCUTANEOUS","productName":"BYNFEZIA Pen"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"OCTREOTIDE ACETATE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Octreotide Acetate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Sandostatin"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Octreotide"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Octreotide Acetate"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147950","MMSL":"1443","NDDF":"002107","UNII":"RWM8CCW8GP","VUID":"4019864","CHEBI":"CHEBI:7726","VANDF":"4019472","INN_ID":"5656","RXNORM":"196457","UMLSCUI":"C0028833","chemblId":"CHEMBL1680","ChEMBL_ID":"CHEMBL1680","KEGG_DRUG":"D00442","DRUGBANK_ID":"DB00104","PUBCHEM_CID":"448601","SNOMEDCT_US":"109053000","IUPHAR_LIGAND_ID":"2055","SECONDARY_CAS_RN":"79517-01-4","MESH_DESCRIPTOR_UI":"D015282"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","company":"Novartis Pharmaceuticals Corporation","brandName":"Sandostatin","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1988-","companyName":"Novartis","relationship":"Original Developer"},{"period":"2020","companyName":"Novartis Pharma K.K., Sandoz K.K.","relationship":"PMDA Licensee"},{"period":"2022","companyName":"Amryt Pharmaceuticals Dac","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.7 hours","clearance":"2.38 mL/min/kg","bioavailability":"2%","fractionUnbound":"0.35%","volumeOfDistribution":"0.19 L/kg"},"publicationCount":9220,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:47.31556+00","atcClassification":{"source":"DrugCentral","atcCode":"H01CB02","allCodes":["H01CB02"]},"biosimilarFilings":[],"originalDeveloper":"Novartis","recentPublications":[{"date":"2026 Mar 27","pmid":"41905700","title":"Effect of octreotide-deoxycholate hydrophobic ion pairing solid dispersions on intestinal permeability to enhance octreotide absorption via increased lipophilicity and ASBT-mediated transport.","journal":"International journal of pharmaceutics"},{"date":"2026 Jan 1","pmid":"41894844","title":"Pulmonary neuroendocrine tumour-associated ectopic Cushing's syndrome: diagnostic challenges and multidisciplinary management.","journal":"Endocrinology, diabetes & metabolism case reports"},{"date":"2026 Mar 17","pmid":"41878918","title":"[Optimal timing for octreotide administration in adult patients with chylothorax: A scoping review].","journal":"Nutricion hospitalaria"},{"date":"2026 Mar 25","pmid":"41877371","title":"Adult-Onset Nesidioblastosis: A Challenging Diagnosis Revealed by Endoscopic Ultrasonography.","journal":"The American journal of case reports"},{"date":"2026 Mar 17","pmid":"41874019","title":"Isolated Blunt Pancreatic Head Injury with Evolving Acute Peripancreatic Fluid Collection in a Child Successfully Managed Conservatively.","journal":"Pediatric reports"}],"companionDiagnostics":[],"genericManufacturers":12,"_genericFilersChecked":true,"genericManufacturerList":["Fresenius Kabi Usa","Gland","Heritage","Meitheal","Mylan Institutional","Mylan Labs Ltd","Sagent Pharms Inc","Shuangcheng","Sun Pharm Inds","Teva Pharms Usa Inc","West-Ward Pharms Int","Wockhardt Usa"],"status":"approved","companyName":"Novartis","companyId":"novartis","modality":"Recombinant protein","firstApprovalDate":"1988","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1988-10-21T00:00:00.000Z","mah":"NOVARTIS","brand_name_local":null,"application_number":""},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2020-08-21T00:00:00.000Z","mah":"Novartis Pharma K.K., Sandoz K.K.","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":12,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:42:02.860752+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}